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MHC Restriction in Three Dimensions: Minireview
A View of T Cell
Receptor/Ligand Interactions
Pamela J. Bjorkman The CDR3 loops of both antibodies and TCRs are a site
of extensive diversity, due to their formation from theDivision of Biology
Howard Hughes Medical Institute assembly of two or more gene segments during lympho-
cyte development. In antibodies, the overall mode ofCalifornia Institute of Technology
Pasadena, California 91125 pairing of variable heavy (VH) with variable light (VL) do-
mains is conserved for all VH±VL combinations, such that
the CDR39s from each domain are at the center of the
site, flanked by the CDR1 and CDR2 regions from eachB and T lymphocytes of the immune system employ a
domain. The same arrangement of CDRs is found in thehighly effective diversity-generating machinery to en-
2C TCR heterodimer structure (Figure 1). Three of thesure that their receptors, antibodies and T cell receptors
TCR heterodimer domains (Va, Vb, and Cb) are structur-(TCRs), respectively, have the capacity to recognize an
ally homologous to their antibody counterparts, but theenormous array of antigens. Indeed, antibodies can be
constant region of the a chain (Ca) shows an unusualraised against many kinds of molecules that are per-
folding topology: instead of the well-characterized bceived as foreign to the host, including proteins, carbo-
sandwich fold of an antibody constant domain or of TCRhydrates, small organic compounds, and nucleic acids.
Cb, in which a conserved disulfide bond spans two bTCRs, on the other hand, have the seemingly peculiar
sheets, the disulfide bond in Ca connects a b strandproperty that they only recognize a foreign antigen when
within an antibody-like b sheet to a helical region in ait is associated with a host- or ªselfº-encoded protein
face that doesn't resemble its antibody counterpart.called a major histocompatibility complex (MHC) mole-
Garcia and colleagues also report the crystallizationcule. The T cell property of ªMHC-restrictedº recognition
of the 2C TCR bound to its MHC/peptide ligand (theof antigen was discovered for cytotoxic T cellsby Zinker-
mouse class I molecule H-2Kb complexed with an oc-nagel and Doherty (1974), work for which they received
tameric self-peptide termed dEV8). Using molecular re-the 1996 Nobel Prize in Medicine.
placement, they determined the positions of both pro-In the intervening 20 plus years, many pivotal discov-
teins in the cocrystal. For the noncrystallographer, thiseries have facilitated a molecular description of MHC-
means that they used the coordinates of the high resolu-restricted T cell recognition (reviewed in Janeway and
tion structures of each protein in a search of the cocrys-Travers, 1996): TCRs werefound to resemble the antigen
tal diffraction data and found rotation and translationbinding, or Fab, portions of antibodies in sequence and
domain organization; the form of antigen recognized by
a TCR was discovered to be a peptide fragment bound
to an MHC molecule; and crystal structures of MHC/
peptide complexes revealed a surface composed of
atoms derived from both the peptide and the MHC mole-
cule. Taken together, these discoveries made the dual
recognition requirements of TCRs (for the right antigen
as well as the right MHC molecule) easier to understand,
butdirect visualization of a TCR binding its MHC/peptide
ligand or even of a TCR alone eluded the efforts of many
laboratories for years. This gap in our knowledge of TCR
recognition has been filled by recent publications of
crystallographic analyses of a TCR heterodimer and of
TCRs binding to their MHC/peptide ligands (Garboczi
et al., 1996; Garcia et al., 1996).
Structure of the 2C TCR
The 2.5 AÊ crystal structure of a mouse TCR ab hetero-
dimer (designated 2C), reported by K. Christopher Gar-
cia, Ian Wilson, and colleagues (Garcia et al., 1996),
confirms what was suspected from the information pro-
vided by TCR sequences and crystal structures of TCR
pieces (Bentley et al., 1995; Fields et al., 1995): the pair-
ing of TCR variable (V) domains is similar to the pairing
of antibody V domains, so that the TCR combining site
for antigen resembles an antibody combining site. In the
combining sites of antibodies, regions of hypervariable
amino acid sequence are located in loops that connect
b strands. The region of contact with antigens primarily Figure 1. Structure of a TCR Heterodimer
involves these loops, which are called complementarity CDR1, yellow; CDR2,green; CDR3,red. Rectangular box in (B) corre-
determining regions (CDRs). Antibody combining sites sponds to pink shaded box in Figure 2B. (2C TCR; Garcia et al.,
1996.)contain sixCDRs, three contributed from each V domain.
Cell
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parameters that describe the location of each molecule Class I and class II MHC molecules have similar three
dimensional structures, both containing a membrane-within the cocrystal unit cell. Having found these param-
eters, they could position the 2C TCR on top of the distal portion consisting of an 8-stranded b-pleated
sheet topped by two a helices (Figure 2; reviewed inH-2Kb/peptide complex. The final structure solution will
include building a model into the electron density maps Stern and Wiley, 1994). In each case, this region is
formed from two subdomains (a1 and a2, class I; a1obtained using the molecular replacement phases, and
refinement of the model. At the reported stage of the and b1, class II), each composed of a 4-stranded b sheet
and a single helix. Short (8±9 residues for class I; 14±20structure determination, a detailed analysis of the mo-
lecular interactions between theTCR and MHC molecule residues for class II) peptides are accommodated within
the groove between the helices. Structural features ofcould not be made, and structural changes in either the
TCR or H-2Kb/peptide complex caused by binding would class I and class II grooves dictate that peptides bind
in only one direction: as depicted in Figures 2B and 2E,not be apparent. However, what most immunologists
really want to know about TCR recognition (i.e., how the N-terminal portion of a peptide is on the left side.
What often comes as a surprise for immunology stu-does a TCR contact the MHC/peptide surface, and do
all TCRs contact MHC/peptide complexes in a similar dents and even seasoned immunologists is that most
of the available surface area of a bound peptide is inac-orientation?) is addressed in this analysis, and the re-
sults can be compared to the 2.6 AÊ refined structure of cessible to a TCR. Thus TCR recognition of a peptide
antigen is accomplished directly by relatively few con-a human TCR/MHC/peptide complex recently reported
by David Garboczi, Partho Ghosh, Don Wiley and col- tacts with peptide side chains that point ªupº (toward
the TCR). Other peptide side chains could be recognizedleagues (Garboczi et al., 1996).
The MHC/Peptide Ligands of TCRs indirectly by subtle conformational changes of MHC res-
idues when different peptides are bound, but for theBefore describing the TCR/MHC/peptide structures, it
is worthwhile to discuss the MHC/peptide ligands that most part, the carbon-a backbones of class I or class
II MHC molecules are remarkably similar regardless ofTCRs recognize. MHC molecules come in two varieties:
class I and class II, which have different cellular distribu- what peptide is bound.
During T cell maturation in the thymus, TCRs are sub-tions and bind different kinds of peptides. Class I MHC
molecules are found on nearly all cells in the body. They jected to two forms of quality control: they must have
some propensity for binding self MHC molecules (posi-present peptides derived from proteins degraded in the
cytosol, alerting the immune system to the presence of tive selection) because they will be required to respond
to foreign peptides complexed with self MHC moleculesintracellular pathogens such as viruses. In general, class
I MHC/peptide complexes are recognized by cytotoxic in the periphery, but they must not bind them too tightly
(negative selection) because of the potential for autoim-T cells that carry the T cell coreceptor CD8, resulting in
killing of the target cell. Class II MHC molecules are mune reactions. Less than 5% of T cells bear receptors
that pass these tests; the rest die in the thymus andexpressed on a more limited subset of cells, mainly
antigen presenting cells involved in interactions with their receptors are not used. TCRs have an intrinsic
affinity for MHC molecules (apparently germ-line en-T cells expressing the coreceptor CD4. Class II MHC
molecules bind peptides derived from exogenous anti- coded according to recent results; Zerrahn et al., 1997),
which might therefore show up as a common mode ofgens, such as proteins engulfed by a macrophage. Rec-
ognition of a class II MHC/peptide complex by a CD4- binding for all TCR/MHC/peptide complexes. The inher-
ent bias of TCRs for MHC recognition could also explainpositive T cell can result in activation of a B cell to
produce antibody, or activation of an infected macro- the large numbers of T cells that react to foreign MHC
molecules (alloreactivity), leading to host rejection ofphage to destroy intracellular bacteria.
Figure 2. Structures of Class I and Class II MHC Molecules
Locations of high points on MHC helices indicated by arrows in (B), (C), (E), and (F). On a ribbon diagram, the high point on the top of the
class II a1 domain is not as pronounced as the other high points, but appears more obvious in surface representations that include side
chains. Approximate footprint of a TCR (rectangular box; see Figure 1B) indicated in (B).
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Figure 3. Structures of TCR/MHC/Peptide
Complexes
Only the V domains of the TCRs are shown.
CDR1, yellow; CDR2, green; CDR3, red. (A
and B) A6/HLA-A2/peptide (Garboczi et al.,
1996; coordinates courtesy of Partho Ghosh).
(C) 2C/Kb/peptide (Garcia et al., 1996; coordi-
nates courtesy of Chris Garcia).
transplanted skin or organs from non-MHC-matched responds. By sequencing TCR genes from T cell hybrid-
omas generated after immunization, the TCR contactdonors.
Mapping TCR Footprints on Their Ligands points for the peptide residues that were changed were
mapped. Results from three peptide variants suggestedThese ideas have prompted a number of studies to map
the orientations of TCRs onto their MHC/peptide li- that CDRs 1 and 2 of TCR a lie over the N-terminal
region of the peptide (left in Figure 2E), CDR3 of the agands. Because the potential for TCR diversity is heavily
concentrated in the CDR3 regions, these loops were chain interacts with a central position of the peptide,
and CDR3 of the b chain lies over the C-terminal regionsuggested to contact the most variable part of the TCR's
MHC/peptide ligand (i.e., the peptide), with the less po- of the peptide (right in Figure 2E), results consistent with
the idea that the TCR is aligned diagonally across thetentially diverse CDR1 and CDR2 loops aligned over the
portion of the TCR ligand that remains more constant MHC/peptide surface, although a detailed comparison
suggests somedifferences between recognition of class(i.e., the MHC helices; reviewed inJorgensen et al., 1992,
and references therein). Two recent studies modify the II and class I molecules by TCRs (Sant'Angelo et al.,
1996).predictions of the earlier models that emphasized
the importance of CDR3 regions in peptide contacts. TCR/MHC/Peptide Structures
With the publication of two crystallographic analyses ofThe first, by Rui Sun and colleagues in the laboratories
of James Sheil and Stanley Nathenson (Sun et al., 1995), TCRs binding to MHC/peptide complexes, immunolo-
gists can finally satisfy their curiousity about MHC re-used a panel of mutants of the mouse class I MHC
molecule, H-2Kb (the MHC molecule recognized by the stricted T cell recognition by looking at three-dimen-
sional representations of the players caught in the act2C TCR) to screen for recognition by 59 different Kb-
specific cytotoxic T lymphocyte clones. Mutations at of binding. In particular, questions about the orientation
of TCRs on their class I MHC/peptide ligands can bethe C-terminal regions of the two helices that form the
sides of the peptide binding groove affected recognition answered, and almost certainly generalized to all TCR
interactions with class I molecules, and perhaps withby most of the clones, but mutations at the N-terminal
regions of the helices did not. Because the helices in class II MHC proteins as well.
Garboczi et al. have solved the structure of a humanMHC molecules are anti-parallel to each other, the re-
sults suggested that TCRs interacting with H-2Kb (and TCR (designated A6) complexed with a class I MHC
molecule (HLA-A2) bound to a viral peptide. The overallprobably with other class I MHC molecules) bind diago-
nally across the MHC/peptide surface (i.e., diagonal to structure of the A6 TCR is similar to the mouse 2C TCR,
although the entire A6 Ca domain is disordered. Thethe a helices but approximately parallel to the b strands)
without contacting the N-terminal regions of each helix. detailed analysis of the A6 interface with the HLA-A2/
peptide complex can be summarized as follows: VaSun et al. note there may be a structural reason for TCRs
to avoid interacting with the N-terminal regions of the CDR1 lies over the N terminus of the peptide, while Vb
CDR3 is aligned over the middle and C-terminal regionsMHC helices: these regions represent the highest points
of the class I MHC surface, so that a TCR binding diago- of the peptide. Additional contacts to the peptide are
made by Va CDR3 near the middle and Vb CDR1 at thenally between these two high points would maximize
contact with MHC and peptide residues (Figures 2B C terminus. This leaves portions of Vb CDR3 and all
three CDRs of Va in contact with the MHC helices. Thisand 2C). The second paper, by Derek Sant'Angelo and
colleagues in Charles Janeway's laboratory (Sant'Angelo orientation is consistent with the orientation of the
mouse 2C TCR on its H-2Kb/peptide ligand, and withet al., 1996), examines TCR contacts to a peptide bound
by the mouse class II MHC molecule, I-Ak. Normal mice the mapping studies of TCRs binding to both class I and
class II/peptide complexes. In particular, the diagonaland mice carrying a transgene encoding either the a or
b chain of a known I-Ak-specific TCR were immunized orientation of the TCR in apparent avoidance of the two
high points on the MHC helices appears striking. Withwith variants of the peptide to which the TCR normally
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the class I molecule in a commonly depicted orientation called agonist peptides; those that result in T cell inhibi-
tion are antagonist peptides. Some peptides elicit only(moosehead view; Figure 3A), the direction of the line
that joins the two centrally located CDR3 loops of the partial T cell responses, and are called partial agonists.
Garboczi et al. announce that they have also crystallizedTCR is z308 from perpendicular to the viewer. When the
MHC molecule is rotated about its long axis (vertical in the A6 TCR as a complex with HLA-A2 and a peptide
that behaves as a partial agonist. The eventual compari-Figure 3) so that the two highest points line up, the
TCR is now aligned with the direction between its CDR3 son of the same TCR interacting with an agonist versus
a partial agonist peptide may shed light on how recogni-regions almost exactly perpendicular to the page. In this
orientation, the MHC a1 and a2 domains resemble a tion of two very similar ligands sends different signals
to the cytoplasm of the T cell. If the A6 TCR shows thesaddle (in both its equine-related and mathematical defi-
nitions), with the A6 TCR appearing as a slightly tilted same conformation when it recognizes both peptides
(as this author suspects it will), mechanisms involving(legless) rider and the 2C TCR seemingly more firmly
seated (Figures 3B and 3C). The tilted orientation of the differences in affinities and/or off-rates that affect the
duration of the binding event (e.g., Matsui et al., 1994),A6 TCR compared to the2C TCR (which might be related
to the greater length of its Vb CDR3 region) results in rather than induced conformational changes, will have
to be invoked to explain the triggering of different cyto-the absence of contacts between CDR2 of the A6 b
chain and MHC or peptide residues on the right side of plasmic signaling pathways following TCR engagement
of the same MHC molecule bearing slightly differentthe groove (as defined in Figure 2B). Judging from the
differences between the A6 and 2C complexes, it seems peptides. Indeed, the issue of how TCR recognition of
anyMHC/peptide complex results in cytoplasmic signal-likely that minor rearrangements of the Va±Vb interface
in other TCRs (as has been observed in comparisons ing remains to be resolved. One next step will be the
comparison of the structure of a TCR in its ligandedof VH±VL domain pairing in antibodies) would place the
CDR2 region of other TCR b chains in position to contact versus unliganded state, undoubtedly a possibility in
the near future. Now that TCRs have been shown tothe C-terminal region of the MHC a1 domain helix, as
appears to be occurring in the interaction between the crystallize, whether produced in eukaryotic (Garcia et
al., 1996) or prokaryotic (Bentley et al., 1995; Fields et2C TCR and its ligand.
Speculations regarding a dimeric TCR/MHC signaling al., 1995; Garboczi et al., 1996) cells, we can look forward
to a multitude of other exciting new structures.assembly (reviewed in Fields and Mariuzza, 1996) are
called into question by both recent TCR structural stud-
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